About Luxsol™ Suspension

Luxsol™ Suspension is one of the few treatments in the USA to receive a Patent granted by the USPTO to treat Covid-19 virus and Influenza:

US Pat. No. 16/881,937 on January 7th, 2021.

Luxsol Suspension

What is Luxsol™ Suspension? Luxsol™ Suspension is a targeted treatment for respiratory illness associated with Covid-19 and influenza. It is not a pill or an injection. It is a spray through the mouth delivering drug directly to lungs using a nebulizer.

Side Effects

Side effects are unknown at this stage, as the drug has not entered human studies. However, based on human experience with Ostrolux™ side effects are expected to be both rare and mild.

History of Luxsol Suspension

  • May 22nd, 2020 Prioritized Examination Pilot Program started. Luxsol Suspension Patent Application was submitted
  • June 4th, 2020 Granted Prioritized Examination Status by USPTO.
  • January 7th, 2021 3V Medical Research Group was notified of the approval of the application to treat Covid-19 and Influenza (Patent approved within 7 months)

Luxsol Suspension was successfully tested in treatment of Covid-19 in an iIn vitro study using Remdesivir as the positive Control. Both drugs were equally effective killing the SARS-COV-2.

Luxsol Suspension is one of the few treatments in the USA to receive a USPTO Patent grant to treat Covid-19 virus and Influenza.

3V Medical Research Group developed Luxsol™ Suspension as a targeted.